Bruker Corporation (NASDAQ:BRKR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Bruker Corporation (NASDAQ:BRKR) has been assigned an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $56.6429.

A number of analysts have recently issued reports on the company. Citigroup cut their price objective on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. JPMorgan Chase & Co. boosted their target price on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Barclays boosted their target price on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Zacks Research raised Bruker from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 4th. Finally, Wolfe Research began coverage on shares of Bruker in a research report on Monday, June 1st. They set a “peer perform” rating for the company.

Bruker Stock Up 0.4%

Bruker stock opened at $57.06 on Thursday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The company’s 50-day moving average is $58.74 and its 200-day moving average is $47.82. The firm has a market capitalization of $8.69 billion, a PE ratio of -81.51, a P/E/G ratio of 1.74 and a beta of 1.28. Bruker has a fifty-two week low of $28.53 and a fifty-two week high of $65.30.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. During the same period last year, the business posted $0.32 EPS. Bruker’s revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts anticipate that Bruker will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio is presently -28.57%.

Institutional Trading of Bruker

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC bought a new position in Bruker in the 4th quarter valued at about $26,000. Global Retirement Partners LLC bought a new stake in shares of Bruker during the second quarter worth approximately $38,000. Parallel Advisors LLC grew its position in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the last quarter. Allworth Financial LP grew its position in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the last quarter. Finally, Essential Partners LLC bought a new position in shares of Bruker during the first quarter worth approximately $36,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.